Compare MTRX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRX | PBYI |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.5M | 263.4M |
| IPO Year | 1990 | N/A |
| Metric | MTRX | PBYI |
|---|---|---|
| Price | $11.91 | $5.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $17.00 | $7.00 |
| AVG Volume (30 Days) | 225.6K | ★ 379.8K |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | ★ $815,591,000.00 | $211,995,000.00 |
| Revenue This Year | $20.43 | N/A |
| Revenue Next Year | $10.64 | N/A |
| P/E Ratio | ★ N/A | $7.50 |
| Revenue Growth | ★ 17.16 | N/A |
| 52 Week Low | $9.33 | $2.58 |
| 52 Week High | $16.11 | $6.12 |
| Indicator | MTRX | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 46.33 | 57.89 |
| Support Level | $11.68 | $5.48 |
| Resistance Level | $12.59 | $5.92 |
| Average True Range (ATR) | 0.42 | 0.21 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 49.44 | 70.37 |
Matrix Service Co provides engineering, fabrication, construction, maintenance, and repair services prominently to the energy and industrial markets. The company operates through three main segments: Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities. These segments cover services like building and maintaining storage tanks and terminals, supporting power delivery and new power generation projects including renewables, as well as plant maintenance and turnarounds for refining and petrochemical industries. Matrix generates revenue by delivering these services to clients in oil, gas, power, and petrochemical sectors across North America and internationally.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.